Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946005 | 1.00 | S1PR1 (0.50) | S1PR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL946007 | 1.00 | S1PR1 (0.50) | S1PR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL945878 | 0.92 | ALDH1A1 (0.47) | S1PR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL945876 | 0.92 | ALDH1A1 (0.47) | S1PR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL945949 | 0.90 | KMT2A (0.50) | S1PR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL945951 | 0.90 | KMT2A (0.50) | S1PR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL944317 | 0.89 | L3MBTL1 (0.54) | ALDH1A1MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL944316 | 0.89 | L3MBTL1 (0.54) | ALDH1A1MEN1KMT2AL3MBTL1KDM4E | |
| SCHEMBL946887 | 0.82 | KMT2A (0.48) | S1PR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL946886 | 0.82 | KMT2A (0.48) | S1PR1ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375426-A1 | PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONIST | VANDA PHARMACEUTICALS INC (US) | 2025-12-11 | — | — | US | claimed |
| EP-3229794-B1 | PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD AND ITS USE IN THE TREATMENT OF MULTIPLE SCLEROSIS | LABORATOIRES JUVISE PHARMACEUTICALS (FR) | 2025-11-05 | — | — | EP | claimed |
| EP-4620526-A2 | PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD AND ITS USE IN THE TREATMENT OF MULTIPLE SCLEROSIS | Laboratoires Juvise Pharmaceuticals (FR) | 2025-09-24 | — | — | EP | claimed |
| US-20250281463-A1 | DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST | VANDA PHARMACEUTICALS INC. | 2025-09-11 | — | — | US | claimed |
| US-12336980-B2 | Dosing regimen for a selective S1P1 receptor agonist | VANDA PHARMACEUTICALS INC. (US) | 2025-06-24 | — | — | US | claimed |
| US-20240139160-A1 | PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONIST | VANDA PHARMACEUTICALS INC. | 2024-05-02 | — | — | US | claimed |
| US-20240131009-A1 | PHARMACEUTICAL COMBINATION COMPRISING A SELECTIVE S1P1 RECEPTOR AGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2024-04-25 | — | — | US | claimed |
| CN-117137912-A | Selectivity S1P 1 Dosing regimen for receptor agonists | 埃科特莱茵药品有限公司 | 2023-12-01 | — | — | CN | claimed |
| US-11771683-B2 | Dosing regimen for a selective S1P1 receptor agonist | ACTELION PHARMACEUTICALS LTD (CH) | 2023-10-03 | — | — | US | claimed |
| US-11672783-B2 | Pharmaceutical combination comprising a selective S1P1 receptor agonist | ACTELION PHARMACEUTICALS LTD (CH) | 2023-06-13 | — | — | US | claimed |
| US-20230131600-A1 | DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2023-04-27 | — | — | US | claimed |
| EP-4056179-A1 | DOSING REGIMEN FOR PONESIMOD, A SELECTIVE S1P1 RECEPTOR AGONIST | Actelion Pharmaceuticals Ltd (CH) | 2022-09-14 | — | — | EP | claimed |
| EP-3256125-B1 | DOSING REGIMEN FOR PONESIMOD, A SELECTIVE S1P1 RECEPTOR AGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2022-01-26 | — | — | EP | claimed |
| US-20260108501-A1 | PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD | VANDA PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260069574-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | VANDA PHARMACEUTICALS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12527772-B2 | Pharmaceutical combination comprising ponesimod | VANDA PHARMACEUTICALS INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220273623-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | VANDA PHARMACEUTICALS INC. | 2022-09-01 | — | — | US | disclosed |
| EP-4003338-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | Actelion Pharmaceuticals Ltd (CH) | 2022-06-01 | — | — | EP | disclosed |
| CN-114144175-A | Methods of treating multiple sclerosis | 埃科特莱茵药品有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3256125-B1 | DOSING REGIMEN FOR PONESIMOD, A SELECTIVE S1P1 RECEPTOR AGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108501-A1 | PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD | TPMT, TSLP, TMPRSS11D | S1PR1 814/4885ALDH1A1 2101/4885MEN1 3248/4885 |
| US-20220273623-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | PMP22, ACHE, CTH | S1PR1 603/4885ALDH1A1 2126/4885MEN1 2089/4885 |
| US-12527772-B2 | Pharmaceutical combination comprising ponesimod | TPMT, TSLP, TPO | S1PR1 418/4885ALDH1A1 1913/4885MEN1 2710/4885 |
| US-20260069574-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | PMP22, SRMS, PLP2 | S1PR1 81/4885ALDH1A1 4189/4885MEN1 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.